MedTrace Logo

Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance

NCT03769766 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 291

Last updated 2025-06-11

No results posted yet for this study

Summary

This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.

Conditions

Interventions

DRUG

Curcumin

Take medication one 500 mg pill of BCM-95 taken twice daily

DRUG

Placebo

Take medication one 500mg pill twice daily

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Yair Lotan, MD · UT Southwestern Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
89 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-11
Primary Completion
2029-11-30
Completion
2030-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03769766 on ClinicalTrials.gov